Allergan PLC (NYSE:AGN) dropped 2.8% during trading on Tuesday . The stock traded as low as $237.85 and last traded at $238.36, with a volume of 3,276,598 shares traded. The stock had previously closed at $245.29.

AGN has been the subject of several research analyst reports. Cowen and Company restated a “buy” rating on shares of Allergan PLC in a research note on Tuesday, May 24th. Bank of America Corp. restated a “buy” rating and set a $294.00 price target (up from $287.00) on shares of Allergan PLC in a research note on Wednesday, June 29th. Leerink Swann restated a “buy” rating on shares of Allergan PLC in a research note on Thursday, June 30th. Wells Fargo & Co. restated a “buy” rating on shares of Allergan PLC in a research note on Friday, June 10th. Finally, Vetr lowered Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $275.94 price target for the company. in a research note on Thursday, June 2nd. Six analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. Allergan PLC has an average rating of “Buy” and an average target price of $308.54.

The stock has a market cap of $94.50 billion, a P/E ratio of 22.72 and a beta of 0.73. The company has a 50-day moving average price of $246.00 and a 200-day moving average price of $243.40.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/allergan-plc-agn-stock-price-down-2-8.html

Allergan PLC (NYSE:AGN) last released its quarterly earnings data on Monday, August 8th. The company reported $3.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.34 by $0.01. The firm earned $3.68 billion during the quarter, compared to analysts’ expectations of $4.10 billion. Allergan PLC had a return on equity of 7.67% and a net margin of 28.06%. The business’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same quarter last year, the firm earned $4.41 earnings per share. On average, analysts expect that Allergan PLC will post $14.01 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the stock. Evercore Wealth Management LLC raised its position in Allergan PLC by 26.2% in the second quarter. Evercore Wealth Management LLC now owns 153,392 shares of the company’s stock valued at $35,448,000 after buying an additional 31,821 shares during the period. Carnick & Kubik Group LLC bought a new position in Allergan PLC during the second quarter valued at $989,000. Williams Jones & Associates LLC raised its position in Allergan PLC by 1.1% in the second quarter. Williams Jones & Associates LLC now owns 110,544 shares of the company’s stock valued at $25,546,000 after buying an additional 1,242 shares during the period. Kentucky Retirement Systems Insurance Trust Fund bought a new position in Allergan PLC during the second quarter valued at $3,691,000. Finally, Kentucky Retirement Systems bought a new position in Allergan PLC during the second quarter valued at $7,773,000. Institutional investors own 85.25% of the company’s stock.

Allergan PLC Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

5 Day Chart for NYSE:AGN

Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.